Eli Lilly joins a troika of Big Pharmas that have tied up to a low-profile biotech with big aspirations in autoimmune disease, cancer

Eli Lilly has followed 3 major league pharma players down the deal path to ImmuNext, a biotech you may not know a whole lot about.

The low-profile biotech has reserved one segment of the R&D mission for immunometabolism, studying how you could regulate the immune system so that it would stop attacking healthy tissue, offering a new approach to autoimmune diseases. Their preclinical program focuses on regulating immune cell metabolism. And that’s where Lilly is stepping on board, joining the program with an aim to advance into human studies.

In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 47,900+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,900+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT
Director of Operations
Atlas Venture Cambridge, MA

Visit Endpoints Careers ->